Treatment of patients with active psoriatic arthritis with sonelokimab — an interleukin -17A- and IL-17F-inhibiting nanobody — led to a higher percentage of patients with 50% or greater improvement in American College of Rheumatology response criteria compared with the placebo in aEligible patients were at least 18 years old with active PsA and had a psoriasis diagnosis.
A total of 207 patients were randomized 1:1:1:1 to every 4 weeks receive placebo, sonelokimab 60 mg with no induction period, sonelokimab 60 mg with induction, and sonelokimab 120 mg with induction.About 46% of patients in the sonelokimab 120-mg and 60-mg groups achieved ACR50 compared with 36.6% in the sonelokimab 60-mg NI group and 20% of those assigned to placebo.
ACR20 and 90% or greater reduction in Psoriasis Area and Severity Index score response rates were higher in all three sonelokimab groups than in the placebo group. There were no unexpected safety findings during the trial, and no cases of inflammatory bowel disease or major cardiovascular events.These data"support further exploration in phase 3 trials of sonelokimab to evaluate its potential for the treatment of PsA," the authors noted in the presentation.Iain B. McInnes, MD, PhD, of the University of Glasgow, Glasgow, Scotland, presented these phase 2 trial results at theMoonLake Immunotherapeutics funded the research.
Skill Checkup: A 48-Year-Old Man With Treated Psoriatic Arthritis and Fatigue, Weakness, and Dull Abdominal PainAll material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC. This website also contains material copyrighted by 3rd parties.